Last reviewed · How we verify
NCT03522155
Patient-Centered Communication of Life Expectancy Estimates in Genitourinary Malignancies
NA trial testing Patient-centered communication of life expectancy in Prostate Cancer Stage I in 136 participants. Status unknown.
30 September 2022
Quick facts
| Lead sponsor | Cedars-Sinai Medical Center |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | health services research |
| Enrollment | 136 |
| Start date | 1 September 2021 |
| Primary completion | 30 September 2022 |
| Estimated completion | 30 September 2023 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Patient-centered communication of life expectancy
Conditions studied
- Prostate Cancer Stage I — all drugs for Prostate Cancer Stage I →
- Kidney Cancer Stage I — all drugs for Kidney Cancer Stage I →
- Bladder Cancer Stage II — all drugs for Bladder Cancer Stage II →
- Prostate Cancer Stage II — all drugs for Prostate Cancer Stage II →
Sponsor
Cedars-Sinai Medical Center
Who can join
18 and older, any sex, with Prostate Cancer Stage I or Kidney Cancer Stage I. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Investigators will conduct a randomized trial to determine if providing patient-specific life expectancy estimates during treatment counseling via a targeted, patient-centered communication approach improves shared decision making and reduces rates of overtreatment of genitourinary malignancies.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03522155
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Prostate Cancer Stage I
Currently open trials in the same condition.
- NCT03789253 — Identify Genes/Pathways Responsible for Progression From Low Risk to Higher Risk Prostate Cancer · recruiting
Other Cedars-Sinai Medical Center trials
Trials by the same sponsor.
- NCT06012487 — Correlates and Control of Blood Pressure Variability · Phase 1 · not yet recruiting
- NCT07495995 — SAMe for Prevention of Liver Cancer in MASLD-Related Cirrhosis · Phase 2 · not yet recruiting
- NCT07413965 — TAVR vs SAVR in Severe Bicuspid Aortic Stenosis · NA · not yet recruiting
- NCT06521021 — CHOICE to AVOID or RESIST · NA · not yet recruiting
- NCT07499089 — Together-Breast Cancer Support Platform · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03522155 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Cedars-Sinai Medical Center
- Last refreshed: 6 February 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03522155.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing